Dr. Jim Tananbaum has been on the forefront of the industry of health care investments as his company Foresite Capital has become a leader in the business, claims patientdaily.com.
The establishment of the Foresite Capital Management has been a turning point for Dr. Jim Tananbaum. His career truly took off seven years ago when he established Foresite Capital in 2010.
Up until that point, Dr. Jim Tananbaum had developed a reputation of an expert in terms of growing a business. Dr. Jim Tananbaum has specialized in the fields of health care and investments. Foresite Capital Management is a combination of both of those businesses. Up to date, the Corporation has offices in several of the states of the US such as Philadelphia, San Francisco, and New York City, among others. The company of Foresite Capital Management invests in other business operating in the fields of genomics, biotech, and more.
Dr. Tananbaum has received an extensive higher education. He is a former student of two of the most renowned academic institutions in the world – Harvard University and Yale University. Dr. Jim Tananbaum has earned a few degrees including a bachelor’s, M. D., M. B. A. and B. S. E. E. He has majored in health care, finance, and business administration. Those majors have helped him establish his successful career.
Over the course of his career as an entrepreneur, Dr. Jim Tananbaum has developed some businesses. Some of them had been sold off to larger companies, and others are still expanding. Examples are GelTex Pharmaceuticals which was purchased for over 2 billion by Genzyme a few years ago. Theravance, on the other hand, is still standing. It is an expanding company that might reach the scale of Foresite Capital someday.
Dr. Jim Tananbaum has also been hired to grow other businesses that he had not created, such as Jazz Pharmaceuticals, Amar group and more, reveals marketwired.com. Many of them were later sold off for up to a few billion dollars. An example of such company is Amira Pharmaceuticals. After Dr. Jim Tananbaum had grown the company to a substantial scale, the Bristol-Myers Squibb Pharmaceutical Institute made a purchase of it.
Visit Dr. Jim Tananbaum‘s Linked In profile to learn more.